secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001386570-26-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen Bioscience Q1 net sales $31.5M (+3% YoY); net income $6.3M up from $5.1M
-------------------------------------------------------------------------------

- Gross margin 63.5%; adjusted EBITDA $3.8M vs $4.9M year ago.
- Launched clinician-directed telehealth platform Niagen Plus and first cruise ship clinic partnership.
- Completed divestiture of Analytical Reference Standards segment to LGC Standards in Feb 2026.
- Board approved $20M share repurchase program; repurchased $2.4M in Q1.
- FY 2026 G&A outlook improved to +$3-4M vs prior +$4-5M; sales & marketing investment to rise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000138657026000031/0001386570-26-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000138657026000031/cdxc-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001386570-26-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer